Detwiler v. Bristol-Myers Squibb Co.

884 F. Supp. 117, 1995 U.S. Dist. LEXIS 5320, 1995 WL 290241
CourtDistrict Court, S.D. New York
DecidedApril 20, 1995
Docket93 Civ. 4507 (LLS)
StatusPublished
Cited by2 cases

This text of 884 F. Supp. 117 (Detwiler v. Bristol-Myers Squibb Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Detwiler v. Bristol-Myers Squibb Co., 884 F. Supp. 117, 1995 U.S. Dist. LEXIS 5320, 1995 WL 290241 (S.D.N.Y. 1995).

Opinion

MEMORANDUM AND ORDER

STANTON, District Judge.

Susan Detwiler sues Dr. Orentreich, 1 who administered injections of silicone into her face, for medical malpractice and fraud. 2 She sues the other defendants on a variety of theories for injuries allegedly caused by silicone gel breast implants. Her husband asserts a claim for loss of consortium against all defendants.

Dr. Orentreich now moves to dismiss the medical malpractice claim as time-barred, and the complaint as faffing to state a claim for fraud. Plaintiffs cross-move for leave to amend the present Amended Complaint.

*119 BACKGROUND

Mrs. Detwiler first sought treatment from Dr. Orentreich in April 1978. (Amended Complaint, ¶ 99.) From then through September 1980, Dr. Orentreich treated her by injecting silicone directly into her facial tissues. (Id. ¶ 100.)

Mrs. Detwiler alleges that Dr. Orentreich provided her with incomplete and inaccurate information about the risks of the. silicone injections. Specifically, she claims he failed to tell her that silicone could cause autoimmune diseases; that her body could reject the silicone; that physical scarring, infection, and pigmentation changes could occur; that the silicone could migrate within her body or shift position; and that silicone had not been approved by the FDA for injection into the human body.

Mrs. Detwiler also claims that Dr. Orentreieh represented that silicone was safe for injection when it was in fact unsafe. (Id. ¶¶ 101-02.) She alleges that Dr. Orentreich knew or should have known of the potential risks at the time he treated her. If she had known about the possible complications, Mrs. Detwiler says, she would not have consented to the treatment. (Id. ¶ 104.) The Detwilers filed their complaint on July 2, 1993.

DISCUSSION

A. Standards

In considering a motion to dismiss under Fed.R.Civ.P. 12(b)(6), “a court must accept the allegations contained in the complaint as true, and draw all reasonable inferences in favor of the non-movant; it should not dismiss the complaint ‘unless it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would entitle him to relief.’” Sheppard v. Beerman, 18 F.3d 147, 150 (2nd Cir.), cert. denied, — U.S. -, 115 S.Ct. 73, 130 L.Ed.2d 28 (1994) (citations omitted).

Fed.R.Civ.P. 15(a) requires that leave to amend “be freely granted when justice so requires.” A district court “is justified in denying an amendment if the proposed amendment could not withstand a motion to dismiss.” Journal Pub. Co. v. American Home Assurance Co., 771 F.Supp. 632, 635 (S.D.N.Y.1991) (internal quotations omitted).

B. Medical Malpractice Claim

Plaintiffs assert a claim against Dr. Orentreich for “professional negligence.” The parties agree that the claim is one of medical malpractice. (See Plaintiffs’ Memorandum, at 11; Defendants’ Memorandum in Support of Motion to Dismiss, at 4-6.)

Under New York law, a medical malpractice action “must be commenced within two years and six months of the act, omission or failure complained of or last treatment where there is continuous treatment for the same illness, injury or condition which gave rise to the said act, omission or failure.” N.Y.Civ. Prac.L. & R. 214-a (McKinney 1995). The medical malpractice claim is time-barred because the action was not commenced until 12 years after Dr. Orentreich last treated Mrs. Detwiler.

A physician may be equitably es-topped from asserting a statute of limitations defense if the plaintiff was induced “by fraud, misrepresentations or deception to refrain from filing a timely action.” Simcuski v. Saeli 44 N.Y.2d 442, 448, 406 N.Y.S.2d 259, 262, 377 N.E.2d 713, 716 (1978). He is es-topped only if he knew of the alleged malpractice before the statute of limitations had run and intentionally concealed it from the patient, inducing reliance and forbearance from suit. Hoemke v. New York Blood Center, 720 F.Supp. 45, 46 (S.D.N.Y.1989), aff'd, 912 F.2d 550 (2nd Cir.1990).

Plaintiffs contend that Dr. Orentreich is estopped from raising the statute of limitations defense. They seek to amend the complaint to allege that Dr. Orentreich made fraudulent representations and failed to make disclosures after the alleged acts of medical malpractice, in an attempt to conceal that malpractice. (Proposed Second Amended Complaint, Conklin Aff.Exh. A, ¶ 108.) Although the Second Amended Complaint does not specify the content of the alleged misrepresentations, plaintiffs’ memorandum makes clear that they rely on Dr. Orentreich’s assertions that the silicone injections were safe and his “willingness to continue to *120 perform the procedure” six or seven times after the initial injection, without disclosing the potential risks to Mrs. Detwiler. (Plaintiffs’ Memorandum, at 13-14.)

Those actions do not estop Dr. Orentreich from raising a statute of limitations defense. The fraudulent acts asserted by plaintiffs are the same acts on which Mrs. Detwiler bases her medical malpractice claim. Under plaintiffs’ approach, Dr. Orentreich was committing malpractice and concealing it at the same time. Equitable estoppel may be invoked only when a physician conceals his prior malpractice, so the doctrine does not apply here.

Plaintiffs also appear to claim that Dr. Orentreich violated a continuing duty to inform Mrs. Detwiler of the potential consequences of the silicone injections: as they say, “This fraudulent conduct never ceased to be operational and was continuing and ongoing.” (Proposed Second Amended Complaint, ¶ 109.) To the extent plaintiffs charge Dr. Orentreich with failing to provide information after he stopped treating Mrs. Detwiler, that failure does not estop him. Despite the fiduciary duty owed by physicians to their patients, physicians are “not required to contact and inform past patients of merely possible harms from treatment that they did not know was negligent or harmful.” Hoemke, 720 F.Supp. at 47.

Thus, plaintiffs have not alleged the intentional fraudulent concealment necessary to estop Dr. Orentreich from raising a statute of limitations defense. Because plaintiffs’ proposed amendment would be futile, their cross-motion to amend the complaint is denied. Dr. Orentreich’s motion to dismiss the medical malpractice claim is granted.

C. Fraud Claim

Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hardaway Management Co. v. Southerland
977 S.W.2d 910 (Kentucky Supreme Court, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
884 F. Supp. 117, 1995 U.S. Dist. LEXIS 5320, 1995 WL 290241, Counsel Stack Legal Research, https://law.counselstack.com/opinion/detwiler-v-bristol-myers-squibb-co-nysd-1995.